|
KMID : 1104820170050010066
|
|
Journal of Digestive Cancer Research
2017 Volume.5 No. 1 p.66 ~ p.69
|
|
|
Response to Capecitabine Treatment Following Palliative Chemotherapy for Metastatic Colorectal Cancer: A Case Report
|
|
Park Dae-Hwa
Kim Ju-Seok
Kang Sun-Hyung
Moon Hee-Seok
Sung Jae-Kyu
Jeong Hyun-Yong
|
|
|
Abstract
|
|
|
|
Approximately 40% of patients with colorectal cancer have metastatic lesions at the time of diagnosis, and chemotherapy is generally prescribed for these patients. Though several drugs are used, 5-FU has long been the backbone of chemotherapy for colorectal cancer. Capecitabine is an oral 5-FU prodrug approved by the FDA in 2005 and is used alone or in combination for treatment of colorectal cancer. Recently, capecitabine has been used for a number of off-label indications, including the treatment of advanced or metastatic colorectal cancer. Here, we report a rare case of a 59-year-old woman, diagnosed with metastatic colorectal cancer who first presented with abdominal discomfort and dyspepsia. She showed a partial response to palliative first line FOLFOX chemotherapy, which had to be stopped due to peripheral neuropathy, as a side effect. She was next put on a second line chemotherapy regimen with capecitabine alone, since then she showed good treatment response without any disease progression.
|
|
|
KEYWORD
|
|
|
Colorectal Cancer, Chemotherapy, Capecitabine
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|